Evidence map›Paper›PMID 39513680›Full record

ArticleJournal of medicinal chemistry2024

A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms.

Alejandro Fernández, Margarida Gairí, María Teresa González, Miquel Pons

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alejandro FernándezBiomolecular NMR Laboratory, Departament de Química Inorgànica i Orgànica, Universitat de Barcelona (UB), Baldiri Reixac 10-12, 08028 Barcelona. Spain.
Margarida GairíCentres Científics i Tecnològics de La Universitat de Barcelona (CCiTUB), Baldiri Reixac 10-12, 08028 Barcelona. Spain.
María Teresa GonzálezCentres Científics i Tecnològics de La Universitat de Barcelona (CCiTUB), Baldiri Reixac 10-12, 08028 Barcelona. Spain.
Miquel PonsBiomolecular NMR Laboratory, Departament de Química Inorgànica i Orgànica, Universitat de Barcelona (UB), Baldiri Reixac 10-12, 08028 Barcelona. Spain.ORCID 0000-0002-0586-8322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methionine residues within the kinase domain of Src serve as unique NMR probes capable of distinguishing between distinct conformational states of full-length Src, including alternative drug-inhibited forms. This approach offers a rapid method to differentiate between various inhibition mechanisms at any stage of drug development, eliminating the need to resolve the structure of Src-drug complexes. Using selectively

Indexed as

Protein Kinase InhibitorsHumansMagnetic Resonance SpectroscopyMethioninesrc-Family KinasesTyrosine Kinase InhibitorsMethionineProtein Kinase Inhibitorssrc-Family KinasesTyrosine Kinase Inhibitors

Identifiers

PMID39513680
PMCPMC11613495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.